Table 2.
Antitumor efficacy in 32 patients who be evaluable by RECIST.
| n = 32† (%) | |
|---|---|
| BOR | |
| Complete response | 1 (3) |
| Partial response | 11 (31) |
| Stable disease | 16 (50) |
| Progressive disease | 4 (13) |
| ORR, % | 37.5 |
| DCR, % | 87.5 |
| Tumor shrinkage by the treatment | |
| Yes | 23 (72) |
| No | 9 (28) |
| Mean change in the sum of tumor diameter from baseline, % [range] | -18.9 [-92 to +84] |
| Mean change in the sum of tumor diameter from baseline, % [range] | -18.9 [-92 to +84] |
| n = 32† (%) | |
| BOR | |
| Complete response | 1 (3) |
| Partial response | 11 (31) |
| Stable disease | 16 (50) |
| Progressive disease | 4 (13) |
| ORR, % | 37.5 |
| DCR, % | 87.5 |
| Tumor shrinkage by the treatment | |
| Yes | 23 (72) |
| No | 9 (28) |
| Mean change in the sum of tumor diameter from baseline, % [range] | -18.9 [-92 to +84] |
†Data were analyzed in 32 evaluable patients. BOR, best overall response; ORR, objective response rate; DCR, disease control rate.